NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. (October 2022)

• Record Type: Journal Article
• Authors: Yap, T.A.; Ngoi, N.; Dumbrava, E.E.; Karp, D.D.; Rodon Ahnert, J.; Fu, S.; Hong, D.S.; Naing, A.; Pant, S.; Piha-Paul, S.A.; Subbiah, V.; Tsimberidou, A.M.; Dufner, D.; Rhudy, J.; Gore, S.; Ivy, S.P.; Yuan, Y.; Westin, S.N.; Mills, G.B.; Meric-Bernstam, F.
• Is Part Of: European journal of cancer. Volume 174(2022)Supplement 1
• Page Start: S7
• Publication Date: 2022-10
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(22)00822-X
• Languages: English
• ISSNs: 0959-8049